Skip to main content

Pharmacogenomics

Guest editor: Matthias Schwab

Efforts to predict and monitor drug response in individuals and in the population have increased markedly over the past few years, but there is a need for replication, targeted resequencing and functional understanding, and for translation of pharmacogenomics research into the clinic. Genome Medicine presents an article collection highlighting this important and fast-moving field.

 This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The guest editor declares no competing interests.

  1. Chronic pain affects approximately one in five adults, resulting in a greatly reduced quality of life and a higher risk of developing co-morbidities such as depression. Available treatments often provide inade...

    Authors: Megan Crow, Franziska Denk and Stephen B McMahon
    Citation: Genome Medicine 2013 5:12
    Content type: Review Published on:

  2. Considerable progress has been made in identifying genetic risk factors for idiosyncratic adverse drug reactions in the past 30 years. These reactions can affect various tissues and organs, including liver, sk...

    Authors: Ann K Daly
    Citation: Genome Medicine 2013 5:5
    Content type: Review Published on:

  3. Although microRNAs (miRNAs) are implicated in osteosarcoma biology and chemoresponse, miRNA prognostic models are still needed, particularly because prognosis is imperfectly correlated with chemoresponse. Form...

    Authors: Andrew D Kelly, Benjamin Haibe-Kains, Katherine A Janeway, Katherine E Hill, Eleanor Howe, Jeffrey Goldsmith, Kyle Kurek, Antonio R Perez-Atayde, Nancy Francoeur, Jian-Bing Fan, Craig April, Hal Schneider, Mark C Gebhardt, Aedin Culhane, John Quackenbush and Dimitrios Spentzos
    Citation: Genome Medicine 2013 5:2
    Content type: Research Published on:

  4. Organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 (encoded by SLCO1B1, SLCO1B3, SLCO2B1) mediate the hepatic uptake of endogenous compounds like bile acids and of drugs, for example, the lip...

    Authors: Anne T Nies, Mikko Niemi, Oliver Burk, Stefan Winter, Ulrich M Zanger, Bruno Stieger, Matthias Schwab and Elke Schaeffeler
    Citation: Genome Medicine 2013 5:1
    Content type: Research Published on:

  6. Glucocorticoids, such as prednisolone, are widely used anti-inflammatory drugs, but therapy is hampered by a broad range of metabolic side effects including skeletal muscle wasting and insulin resistance. Ther...

    Authors: Sandrine Ellero-Simatos, Ewa Szymańska, Ton Rullmann, Wim HA Dokter, Raymond Ramaker, Ruud Berger, Thijs MP van Iersel, Age K Smilde, Thomas Hankemeier and Wynand Alkema
    Citation: Genome Medicine 2012 4:94
    Content type: Research Published on:

  7. The goal of personalized medicine is to tailor a patient's treatment strategy on the basis of his or her unique genetic make-up. The field of oncology is beginning to incorporate many of the strategies of pers...

    Authors: Erika L Moen, Lucy A Godley, Wei Zhang and M Eileen Dolan
    Citation: Genome Medicine 2012 4:90
    Content type: Review Published on:

  9. Translation of pharmacogenomics to public health action is at the epicenter of the life sciences agenda. Post-genomics knowledge is simultaneously co-produced at multiple scales and locales by scientists, crow...

    Authors: Edward S Dove, Samer A Faraj, Eugene Kolker and Vural Özdemir
    Citation: Genome Medicine 2012 4:91
    Content type: Opinion Published on: